The reliance of monocytic AML cells on MCL-1 rather than BCL-2 seems to be the underlying reason for selection of a pre-existing monocytic subpopulation at the time of relapse following ven/aza therapy [123]. This evidence concerns the gene BCL2 and acute myeloid leukemia.